We have a successful record of research collaborations, in areas such as oncology, with partners including Novartis (now advanced into Phase II clinical studies), Servier, Genentech, GSK, Lundbeck, Daiichi Sankyo and Asahi Kasei Pharma . Vernalis’ structure- and fragment-based drug discovery expertise is available to support a variety of target-specific collaborations.
We continue to seek further research collaborations. Contact us to discuss our particular research expertise, with a view to possible joint research projects.
Contact us >
See our current research collaborations